-
1
-
-
33644851056
-
Tissue factor in cardiovascular diseases: Molecular mechanisms and clinical implications
-
Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006;113:722-731.
-
(2006)
Circulation
, vol.113
, pp. 722-731
-
-
Steffel, J.1
Luscher, T.F.2
Tanner, F.C.3
-
3
-
-
4644230820
-
The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
-
DOI 10.1378/chest.126.3-suppl.204S
-
Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl. 3):204S-233S. (Pubitemid 39297955)
-
(2004)
Chest
, vol.126
, Issue.3 SUPPL.
-
-
Ansell, J.1
Hirsh, J.2
Poller, L.3
Bussey, H.4
Jacobson, A.5
Hijlek, E.6
-
4
-
-
34347394385
-
Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
-
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867. (Pubitemid 351650486)
-
(2007)
Annals of Internal Medicine
, vol.146
, Issue.12
, pp. 857-867
-
-
Hart, R.G.1
Pearce, L.A.2
Aguilar, M.I.3
-
5
-
-
19344366484
-
Systematic overview of warfarin and its drug and food interactions
-
DOI 10.1001/archinte.165.10.1095
-
Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-1106. (Pubitemid 40720733)
-
(2005)
Archives of Internal Medicine
, vol.165
, Issue.10
, pp. 1095-1106
-
-
Holbrook, A.M.1
Pereira, J.A.2
Labiris, R.3
McDonald, H.4
Douketis, J.D.5
Crowther, M.6
Wells, P.S.7
-
6
-
-
0142135442
-
Warfarin and other coumarin derivatives: Pharmacokinetics, pharmacodynamics, and drug interactions
-
DOI 10.1055/s-2003-44457
-
Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med 2003;3:221-230. (Pubitemid 37280710)
-
(2003)
Seminars in Vascular Medicine
, vol.3
, Issue.3
, pp. 221-230
-
-
Wittkowsky, A.K.1
-
7
-
-
0023067985
-
Warfarin metabolism and drug-drug interactions
-
O'Reilly RA. Warfarin metabolism and drug-drug interactions. Adv Exp Med Biol 1987;214:205-212.
-
(1987)
Adv Exp Med Biol
, vol.214
, pp. 205-212
-
-
O'Reilly, R.A.1
-
8
-
-
45949108549
-
Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
-
DOI 10.1378/chest.08-0652
-
Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl. 6):110S-112S. (Pubitemid 351892962)
-
(2008)
Chest
, vol.133
, Issue.6 SUPPL. 6
-
-
Hirsh, J.1
Guyatt, G.2
Albers, G.W.3
Harrington, R.4
Schunemann, H.J.5
-
9
-
-
77957738116
-
Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
-
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Vardas PE, Agladze V, Aliot E, Balabanski T, Blomstrom-Lundqvist C, Capucci A, Crijns H, Dahlof B, Folliguet T, Glikson M, Goethals M, Gulba DC, Ho SY, Klautz RJ, Kose S, McMurray J, Perrone Filardi P, Raatikainen P, Salvador MJ, Schalij MJ, Shpektor A, Sousa J, Stepinska J, Uuetoa H, Zamorano JL, Zupan I. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12:1360-1420.
-
(2010)
Europace
, vol.12
, pp. 1360-1420
-
-
Camm, A.J.1
Kirchhof, P.2
Lip, G.Y.3
Schotten, U.4
Savelieva, I.5
Ernst, S.6
Van Gelder, I.C.7
Al-Attar, N.8
Hindricks, G.9
Prendergast, B.10
Heidbuchel, H.11
Alfieri, O.12
Angelini, A.13
Atar, D.14
Colonna, P.15
De Caterina, R.16
De Sutter, J.17
Goette, A.18
Gorenek, B.19
Heldal, M.20
Hohloser, S.H.21
Kolh, P.22
Le Heuzey, J.Y.23
Ponikowski, P.24
Rutten, F.H.25
Vahanian, A.26
Auricchio, A.27
Bax, J.28
Ceconi, C.29
Dean, V.30
Filippatos, G.31
Funck-Brentano, C.32
Hobbs, R.33
Kearney, P.34
McDonagh, T.35
Popescu, B.A.36
Reiner, Z.37
Sechtem, U.38
Sirnes, P.A.39
Tendera, M.40
Vardas, P.E.41
Widimsky, P.42
Vardas, P.E.43
Agladze, V.44
Aliot, E.45
Balabanski, T.46
Blomstrom-Lundqvist, C.47
Capucci, A.48
Crijns, H.49
Dahlof, B.50
Folliguet, T.51
Glikson, M.52
Goethals, M.53
Gulba, D.C.54
Ho, S.Y.55
Klautz, R.J.56
Kose, S.57
McMurray, J.58
Perrone Filardi, P.59
Raatikainen, P.60
Salvador, M.J.61
Schalij, M.J.62
Shpektor, A.63
Sousa, J.64
Stepinska, J.65
Uuetoa, H.66
Zamorano, J.L.67
Zupan, I.68
more..
-
10
-
-
68349093744
-
Novel anticoagulants in clinical development: Focus on factor Xa and direct thrombin inhibitors
-
Steffel J, Luscher TF. Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. J Cardiovasc Med (Hagerstown, MD) 2009;10: 616-623.
-
(2009)
J Cardiovasc Med (Hagerstown, MD)
, vol.10
, pp. 616-623
-
-
Steffel, J.1
Luscher, T.F.2
-
11
-
-
34548031359
-
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
-
DOI 10.1111/j.1365-2125.2007.02899.x
-
Stangier J, Rathgen K, Stahle H, Gansser D, RothW. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303. (Pubitemid 47283865)
-
(2007)
British Journal of Clinical Pharmacology
, vol.64
, Issue.3
, pp. 292-303
-
-
Stangier, J.1
Rathgen, K.2
Stahle, H.3
Gansser, D.4
Roth, W.5
-
12
-
-
41949116970
-
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
-
DOI 10.2165/00003088-200847050-00001
-
Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-295. (Pubitemid 351508116)
-
(2008)
Clinical Pharmacokinetics
, vol.47
, Issue.5
, pp. 285-295
-
-
Stangier, J.1
-
13
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
-
(2009)
N Engl J Med
, vol.361
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
Eikelboom, J.4
Oldgren, J.5
Parekh, A.6
Pogue, J.7
Reilly, P.A.8
Themeles, E.9
Varrone, J.10
Wang, S.11
Alings, M.12
Xavier, D.13
Zhu, J.14
Diaz, R.15
Lewis, B.S.16
Darius, H.17
Diener, H.C.18
Joyner, C.D.19
Wallentin, L.20
more..
-
14
-
-
78049490509
-
Newly identified events in the RE-LY trial
-
Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-1876.
-
(2010)
N Engl J Med
, vol.363
, pp. 1875-1876
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
Reilly, P.A.4
Wallentin, L.5
-
15
-
-
77949312944
-
Drug-induced liver injury in humans: The case of ximelagatran
-
Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010;196:407-418.
-
(2010)
Handb Exp Pharmacol
, vol.196
, pp. 407-418
-
-
Keisu, M.1
Andersson, T.B.2
-
16
-
-
78349313002
-
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE-LY trial
-
Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:1157-1163
-
(2010)
Lancet Neurol
, vol.9
, pp. 1157-1163
-
-
Diener, H.C.1
Connolly, S.J.2
Ezekowitz, M.D.3
Wallentin, L.4
Reilly, P.A.5
Yang, S.6
Xavier, D.7
Di Pasquale, G.8
Yusuf, S.9
-
18
-
-
78751637313
-
Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion
-
Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation; 2011;123:131-136.
-
(2011)
Circulation
, vol.123
, pp. 131-136
-
-
Nagarakanti, R.1
Ezekowitz, M.D.2
Oldgren, J.3
Yang, S.4
Chernick, M.5
Aikens, T.H.6
Flaker, G.7
Brugada, J.8
Kamensky, G.9
Parekh, A.10
Reilly, P.A.11
Yusuf, S.12
Connolly, S.J.13
-
19
-
-
77956977472
-
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial
-
Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-983.
-
(2010)
Lancet
, vol.376
, pp. 975-983
-
-
Wallentin, L.1
Yusuf, S.2
Ezekowitz, M.D.3
Alings, M.4
Flather, M.5
Franzosi, M.G.6
Pais, P.7
Dans, A.8
Eikelboom, J.9
Oldgren, J.10
Pogue, J.11
Reilly, P.A.12
Yang, S.13
Connolly, S.J.14
-
20
-
-
79952445042
-
ACCF/AHA/HRS Focused Update on the Management of Patients with Atrial Fibrillation (Update on Dabigatran)
-
Published online ahead of print 10 February
-
Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WJ, Tracy CM. ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran). J Am Coll Cardiol. Published online ahead of print 10 February 2011.
-
(2011)
J Am Coll Cardiol
-
-
Wann, L.S.1
Curtis, A.B.2
Ellenbogen, K.A.3
Estes Iii, N.A.4
Ezekowitz, M.D.5
Jackman, W.M.6
January, C.T.7
Lowe, J.E.8
Page, R.L.9
Slotwiner, D.J.10
Stevenson, W.J.11
Tracy, C.M.12
-
21
-
-
35449007749
-
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial
-
DOI 10.1111/j.1538-7836.2007.02748.x
-
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-2185. (Pubitemid 47617868)
-
(2007)
Journal of Thrombosis and Haemostasis
, vol.5
, Issue.11
, pp. 2178-2185
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
Kurth, A.A.4
Van Dijk, C.N.5
Frostick, S.P.6
Kalebo, P.7
Christiansen, A.V.8
Hantel, S.9
Hettiarachchi, R.10
Schnee, J.11
Buller, H.R.12
-
22
-
-
34548575058
-
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
-
DOI 10.1016/S0140-6736(07)61445-7, PII S0140673607614457
-
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370: 949-956. (Pubitemid 47393577)
-
(2007)
Lancet
, vol.370
, Issue.9591
, pp. 949-956
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
Kurth, A.A.4
Van Dijk, C.N.5
Frostick, S.P.6
Prins, M.H.7
Hettiarachchi, R.8
Hantel, S.9
Schnee, J.10
Buller, H.R.11
-
23
-
-
77953791161
-
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials
-
Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010;126:175-182.
-
(2010)
Thromb Res
, vol.126
, pp. 175-182
-
-
Friedman, R.J.1
Dahl, O.E.2
Rosencher, N.3
Caprini, J.A.4
Kurth, A.A.5
Francis, C.W.6
Clemens, A.7
Hantel, S.8
Schnee, J.M.9
Eriksson, B.I.10
-
24
-
-
79953836474
-
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) A randomised, double-blind, noninferiority trial
-
[Epub ahead of print]
-
Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, noninferiority trial. Thromb Haemost 2011;105. [Epub ahead of print].
-
(2011)
Thromb Haemost
, pp. 105
-
-
Eriksson, B.I.1
Dahl, O.E.2
Huo, M.H.3
Kurth, A.A.4
Hantel, S.5
Hermansson, K.6
Schnee, J.M.7
Friedman, R.J.8
-
25
-
-
71849117615
-
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
-
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-2352.
-
(2009)
N Engl J Med
, vol.361
, pp. 2342-2352
-
-
Schulman, S.1
Kearon, C.2
Kakkar, A.K.3
Mismetti, P.4
Schellong, S.5
Eriksson, H.6
Baanstra, D.7
Schnee, J.8
Goldhaber, S.Z.9
-
27
-
-
33645498094
-
Comparison of fondaparinux and enoxaparin in acute coronary syndromes
-
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP,Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476.
-
(2006)
N Engl J Med
, vol.354
, pp. 1464-1476
-
-
Yusuf, S.1
Mehta, S.R.2
Chrolavicius, S.3
Afzal, R.4
Pogue, J.5
Granger, C.B.6
Budaj, A.7
Peters, R.J.8
Bassand, J.P.9
Wallentin, L.10
Joyner, C.11
Fox, K.A.12
-
28
-
-
33645497961
-
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial
-
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-1530.
-
(2006)
JAMA
, vol.295
, pp. 1519-1530
-
-
Yusuf, S.1
Mehta, S.R.2
Chrolavicius, S.3
Afzal, R.4
Pogue, J.5
Granger, C.B.6
Budaj, A.7
Peters, R.J.8
Bassand, J.P.9
Wallentin, L.10
Joyner, C.11
Fox, K.A.12
-
29
-
-
44449100797
-
Idraparinux: Review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders
-
DOI 10.1517/13543784.17.5.773
-
Prandoni P, Tormene D, Perlati M, Brandolin B, Spiezia L. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. Expert Opin Investig Drugs 2008;17:773-777. (Pubitemid 351843619)
-
(2008)
Expert Opinion on Investigational Drugs
, vol.17
, Issue.5
, pp. 773-777
-
-
Prandoni, P.1
Tormene, D.2
Perlati, M.3
Brandolin, B.4
Spiezia, L.5
-
30
-
-
70449598269
-
Development of idraparinux and idrabiotaparinux for anticoagulant therapy
-
Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 2009;102:811-815.
-
(2009)
Thromb Haemost
, vol.102
, pp. 811-815
-
-
Harenberg, J.1
-
31
-
-
77952703086
-
Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion
-
Paty I, Trellu M, Destors JM, Cortez P, Boelle E, Sanderink G. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010;8:722-729.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 722-729
-
-
Paty, I.1
Trellu, M.2
Destors, J.M.3
Cortez, P.4
Boelle, E.5
Sanderink, G.6
-
32
-
-
84857100961
-
-
NCT00580216 at 1st November 2010
-
NCT00580216 at http://www.clinicaltrials.gov/(1st November 2010).
-
-
-
-
33
-
-
78650941964
-
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis
-
Equinox investigators
-
Equinox investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2010;9:92-99.
-
(2010)
J Thromb Haemost
, vol.9
, pp. 92-99
-
-
-
34
-
-
22844442726
-
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - An oral, direct Factor Xa inhibitor
-
DOI 10.1111/j.1538-7836.2005.01166.x
-
Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005;3:514-521. (Pubitemid 41632877)
-
(2005)
Journal of Thrombosis and Haemostasis
, vol.3
, Issue.3
, pp. 514-521
-
-
Perzborn, E.1
Strassburger, J.2
Wilmen, A.3
Pohlmann, J.4
Roehrig, S.5
Schlemmer, K.-H.6
Straub, A.7
-
35
-
-
77649149260
-
Rivaroxaban: A new oral factor Xa inhibitor
-
Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010;30:376-381.
-
(2010)
Arterioscler Thromb Vasc Biol
, vol.30
, pp. 376-381
-
-
Perzborn, E.1
Roehrig, S.2
Straub, A.3
Kubitza, D.4
Mueck, W.5
Laux, V.6
-
37
-
-
45949099359
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
-
DOI 10.1056/NEJMoa0800374
-
Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358: 2765-2775. (Pubitemid 351930851)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.26
, pp. 2765-2775
-
-
Eriksson, B.I.1
Borris, L.C.2
Friedman, R.J.3
Haas, S.4
Huisman, M.V.5
Kakkar, A.K.6
Bandel, T.J.7
Beckmann, H.8
Muehlhofer, E.9
Misselwitz, F.10
Geerts, W.11
-
38
-
-
45949103416
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
-
DOI 10.1056/NEJMoa076016
-
Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-2786. (Pubitemid 351930852)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.26
, pp. 2776-2786
-
-
Lassen, M.R.1
Ageno, W.2
Borris, L.C.3
Lieberman, J.R.4
Rosencher, N.5
Bandel, T.J.6
Misselwitz, F.7
Turpie, A.G.G.8
-
39
-
-
65549169515
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
-
Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-1680.
-
(2009)
Lancet
, vol.373
, pp. 1673-1680
-
-
Turpie, A.G.1
Lassen, M.R.2
Davidson, B.L.3
Bauer, K.A.4
Gent, M.5
Kwong, L.M.6
Cushner, F.D.7
Lotke, P.A.8
Berkowitz, S.D.9
Bandel, T.J.10
Benson, A.11
Misselwitz, F.12
Fisher, W.D.13
-
40
-
-
46049106502
-
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
-
Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-39.
-
(2008)
Lancet
, vol.372
, pp. 31-39
-
-
Kakkar, A.K.1
Brenner, B.2
Dahl, O.E.3
Eriksson, B.I.4
Mouret, P.5
Muntz, J.6
Soglian, A.G.7
Pap, A.F.8
Misselwitz, F.9
Haas, S.10
-
41
-
-
79952496003
-
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty Pooled analysis of four studies
-
Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011;105:444-453.
-
(2011)
Thromb Haemost
, vol.105
, pp. 444-453
-
-
Turpie, A.G.1
Lassen, M.R.2
Eriksson, B.I.3
Gent, M.4
Berkowitz, S.D.5
Misselwitz, F.6
Bandel, T.J.7
Homering, M.8
Westermeier, T.9
Kakkar, A.K.10
-
42
-
-
78650619315
-
Oral rivaroxaban for symptomatic venous thromboembolism
-
The EINSTEIN Investigators
-
The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-2510
-
(2010)
N Engl J Med
, vol.363
, pp. 2499-2510
-
-
-
43
-
-
67649562905
-
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial
-
Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38.
-
(2009)
Lancet
, vol.374
, pp. 29-38
-
-
Mega, J.L.1
Braunwald, E.2
Mohanavelu, S.3
Burton, P.4
Poulter, R.5
Misselwitz, F.6
Hricak, V.7
Barnathan, E.S.8
Bordes, P.9
Witkowski, A.10
Markov, V.11
Oppenheimer, L.12
Gibson, C.M.13
-
45
-
-
42149172523
-
Apixaban, an oral, direct and highly selective factor Xa inhibitor: In vitro, antithrombotic and antihemostatic studies
-
DOI 10.1111/j.1538-7836.2008.02939.x
-
Wong PC, Crain EJ, Xin B,Wexler RR, Lam PY, Pinto DJ, Luettgen JM, Knabb RM. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008;6:820-829. (Pubitemid 351524543)
-
(2008)
Journal of Thrombosis and Haemostasis
, vol.6
, Issue.5
, pp. 820-829
-
-
Wong, P.C.1
Crain, E.J.2
Xin, B.3
Wexler, R.R.4
Lam, P.Y.S.5
Pinto, D.J.6
Luettgen, J.M.7
Knabb, R.M.8
-
46
-
-
64849114048
-
Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro
-
Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 2009;101:780-782.
-
(2009)
Thromb Haemost
, vol.101
, pp. 780-782
-
-
Jiang, X.1
Crain, E.J.2
Luettgen, J.M.3
Schumacher, W.A.4
Wong, P.C.5
-
47
-
-
58149458160
-
Apixaban metabolism and pharmacokinetics after oral administration to humans
-
Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81.
-
(2009)
Drug Metab Dispos
, vol.37
, pp. 74-81
-
-
Raghavan, N.1
Frost, C.E.2
Yu, Z.3
He, K.4
Zhang, H.5
Humphreys, W.G.6
Pinto, D.7
Chen, S.8
Bonacorsi, S.9
Wong, P.C.10
Zhang, D.11
-
48
-
-
77649249878
-
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale
-
Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-339.
-
(2010)
Am Heart J
, vol.159
, pp. 331-339
-
-
Lopes, R.D.1
Alexander, J.H.2
Al-Khatib, S.M.3
Ansell, J.4
Diaz, R.5
Easton, J.D.6
Gersh, B.J.7
Granger, C.B.8
Hanna, M.9
Horowitz, J.10
Hylek, E.M.11
McMurray, J.J.12
Verheugt, F.W.13
Wallentin, L.14
-
49
-
-
68249158084
-
Apixaban or enoxaparin for thromboprophylaxis after knee replacement
-
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361:594-604.
-
(2009)
N Engl J Med
, vol.361
, pp. 594-604
-
-
Lassen, M.R.1
Raskob, G.E.2
Gallus, A.3
Pineo, G.4
Chen, D.5
Portman, R.J.6
-
50
-
-
77649113258
-
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial
-
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-815.
-
(2010)
Lancet
, vol.375
, pp. 807-815
-
-
Lassen, M.R.1
Raskob, G.E.2
Gallus, A.3
Pineo, G.4
Chen, D.5
Hornick, P.6
-
51
-
-
79851483966
-
Apixaban versus enoxaparin in patients with total knee arthroplasty A meta-analysis of randomised trials
-
Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost 2010;105:245-253.
-
(2010)
Thromb Haemost
, vol.105
, pp. 245-253
-
-
Huang, J.1
Cao, Y.2
Liao, C.3
Wu, L.4
Gao, F.5
-
52
-
-
78650587760
-
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement
-
Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363:2487-2498.
-
(2010)
N Engl J Med
, vol.363
, pp. 2487-2498
-
-
Lassen, M.R.1
Gallus, A.2
Raskob, G.E.3
Pineo, G.4
Chen, D.5
Ramirez, L.M.6
-
53
-
-
47649098524
-
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
-
DOI 10.1111/j.1538-7836.2008.03054.x
-
Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008;6:1313-1318. (Pubitemid 352016310)
-
(2008)
Journal of Thrombosis and Haemostasis
, vol.6
, Issue.8
, pp. 1313-1318
-
-
Buller, H.1
Deitchman, D.2
Prins, M.3
Segers, A.4
-
54
-
-
67649563209
-
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
-
Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119: 2877-2885.
-
(2009)
Circulation
, vol.119
, pp. 2877-2885
-
-
Alexander, J.H.1
Becker, R.C.2
Bhatt, D.L.3
Cools, F.4
Crea, F.5
Dellborg, M.6
Fox, K.A.7
Goodman, S.G.8
Harrington, R.A.9
Huber, K.10
Husted, S.11
Lewis, B.S.12
Lopez-Sendon, J.13
Mohan, P.14
Montalescot, G.15
Ruda, M.16
Ruzyllo, W.17
Verheugt, F.18
Wallentin, L.19
-
55
-
-
77953787643
-
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers
-
Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-753.
-
(2010)
J Clin Pharmacol
, vol.50
, pp. 743-753
-
-
Ogata, K.1
Mendell-Harary, J.2
Tachibana, M.3
Masumoto, H.4
Oguma, T.5
Kojima, M.6
Kunitada, S.7
-
57
-
-
77957932391
-
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)
-
Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-641.
-
(2010)
Am Heart J
, vol.160
, pp. 635-641
-
-
Ruff, C.T.1
Giugliano, R.P.2
Antman, E.M.3
Crugnale, S.E.4
Bocanegra, T.5
Mercuri, M.6
Hanyok, J.7
Patel, I.8
Shi, M.9
Salazar, D.10
McCabe, C.H.11
Braunwald, E.12
-
58
-
-
60549096887
-
Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated
-
Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009;40:235-240.
-
(2009)
Stroke
, vol.40
, pp. 235-240
-
-
Gladstone, D.J.1
Bui, E.2
Fang, J.3
Laupacis, A.4
Lindsay, M.P.5
Tu, J.V.6
Silver, F.L.7
Kapral, M.K.8
-
61
-
-
79851482951
-
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
-
Lindahl TL, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2010;105: 371-378
-
(2010)
Thromb Haemost
, vol.105
, pp. 371-378
-
-
Lindahl, T.L.1
Baghaei, F.2
Fagerberg Blixter, I.3
Gustafsson, K.M.4
Stigendal, L.5
Sten-Linder, M.6
Strandberg, K.7
Hillarp, A.8
-
62
-
-
77953168824
-
Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
-
van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-1127.
-
(2010)
Thromb Haemost
, vol.103
, pp. 1116-1127
-
-
Van Ryn, J.1
Stangier, J.2
Haertter, S.3
Liesenfeld, K.H.4
Wienen, W.5
Feuring, M.6
Clemens, A.7
-
63
-
-
78650965540
-
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
-
Hillarp A, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011;9:133-139.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 133-139
-
-
Hillarp, A.1
Baghaei, F.2
Blixter, I.F.3
Gustafsson, K.M.4
Stigendal, L.5
Sten-Linder, M.6
Strandberg, K.7
Lindahl, T.L.8
-
64
-
-
78650271337
-
Assays for measuring rivaroxaban: Their suitability and limitations
-
Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Therapeutic drug monitoring 2010;32: 673-679.
-
(2010)
Therapeutic Drug Monitoring
, vol.32
, pp. 673-679
-
-
Lindhoff-Last, E.1
Samama, M.M.2
Ortel, T.L.3
Weitz, J.I.4
Spiro, T.E.5
-
65
-
-
78649736882
-
Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
-
Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010;104:1263-1271.
-
(2010)
Thromb Haemost
, vol.104
, pp. 1263-1271
-
-
Barrett, Y.C.1
Wang, Z.2
Frost, C.3
Shenker, A.4
-
66
-
-
63149098718
-
Laboratory monitoring of anticoagulation: Where do we stand?
-
Tripodi A, van den Besselaar A. Laboratory monitoring of anticoagulation: where do we stand? Semin Thromb Hemost 2009;35:34-41.
-
(2009)
Semin Thromb Hemost
, vol.35
, pp. 34-41
-
-
Tripodi, A.1
Van Den Besselaar, A.2
-
67
-
-
79952301326
-
The AVERROES steering committee and investigators. Apixaban in patients with atrial fibrillation
-
Feb 10. [Epub ahead of print]
-
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; the AVERROES Steering Committee and Investigators. Apixaban in Patients with Atrial Fibrillation. N Engl J Med 2011 Feb 10. [Epub ahead of print].
-
(2011)
N Engl J Med
-
-
Connolly, S.J.1
Eikelboom, J.2
Joyner, C.3
Diener, H.C.4
Hart, R.5
Golitsyn, S.6
Flaker, G.7
Avezum, A.8
Hohnloser, S.H.9
Diaz, R.10
Talajic, M.11
Zhu, J.12
Pais, P.13
Budaj, A.14
Parkhomenko, A.15
Jansky, P.16
Commerford, P.17
Tan, R.S.18
Sim, K.H.19
Lewis, B.S.20
Van Mieghem, W.21
Lip, G.Y.22
Kim, J.H.23
Lanas-Zanetti, F.24
Gonzalez-Hermosillo, A.25
Dans, A.L.26
Munawar, M.27
O'Donnell, M.28
Lawrence, J.29
Lewis, G.30
Afzal, R.31
Yusuf, S.32
more..
-
68
-
-
79551589662
-
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation
-
Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. Ann Intern Med 2011;154:1-11.
-
(2011)
Ann Intern Med
, vol.154
, pp. 1-11
-
-
Freeman, J.V.1
Zhu, R.P.2
Owens, D.K.3
Garber, A.M.4
Hutton, D.W.5
Go, A.S.6
Wang, P.J.7
Turakhia, M.P.8
-
69
-
-
57649123692
-
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
-
Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. The Journal of arthroplasty 2009;24:1-9.
-
(2009)
The Journal of Arthroplasty
, vol.24
, pp. 1-9
-
-
Ginsberg, J.S.1
Davidson, B.L.2
Comp, P.C.3
Francis, C.W.4
Friedman, R.J.5
Huo, M.H.6
Lieberman, J.R.7
Muntz, J.E.8
Raskob, G.E.9
Clements, M.L.10
Hantel, S.11
Schnee, J.M.12
Caprini, J.A.13
|